Ligand to Showcase Royalty-Driven Strategy at March Conferences

JUPITER, Fla. – March 04, 2026 – Ligand Pharmaceuticals is preparing for a pivotal month of investor engagement, announcing its participation in three prominent healthcare finance conferences. The move signals a concerted effort to communicate the strength of its unique, royalty-focused business model directly to the financial community following a year of exceptional growth and strategic positioning.

Company management is scheduled for a busy agenda, beginning with one-on-one meetings at the Leerink Partners Global Healthcare Conference in Miami on March 11. The tour will continue with a formal presentation at the 38th Annual ROTH Conference in Dana Point, California, on March 23, followed by another presentation at the Nordic-American Healthcare Conference in New York on March 25. These events provide a critical platform for Ligand to detail its recent successes and outline its strategy for deploying over a billion dollars in capital.

A Strategic Roadshow Amidst Strong Performance

The timing of this investor roadshow is no coincidence. Ligand enters the spring conference season on the back of a robust financial performance in 2025 that significantly outpaced expectations. The company reported full-year core revenue of $240 million, a 43% year-over-year increase, driven by a powerful surge in its royalty business. Royalty receipts grew by an impressive 48% to reach $176.9 million, underscoring the escalating value of its diverse portfolio.

The fourth quarter of 2025 was particularly strong, with total revenues climbing 39% to $59.7 million and adjusted earnings per share of $2.02, handily beating analyst consensus. This momentum has allowed Ligand to reaffirm its confident outlook for 2026, projecting total revenues between $245 million and $285 million and royalty revenue growth of approximately 32% at the midpoint. The company's long-term forecast anticipates a compound annual growth rate for royalty receipts exceeding 23% through 2030, a figure that is sure to capture investor attention.

These conferences—Leerink, known for its institutional focus; ROTH, a hub for growth-oriented companies; and the Nordic-American, with its international and innovation-centric audience—offer Ligand a tailored opportunity to articulate this growth story to different segments of the investment world.

The Ligand Blueprint: De-Risking Biotech Investment

At the heart of Ligand's pitch is its distinctive business model, which diverges sharply from the high-risk, capital-intensive path of traditional drug development. Instead of pouring billions into its own R&D, Ligand operates as a strategic enabler and financial partner, creating value through a multi-pronged approach: financing promising mid-to-late-stage drug programs, purchasing royalty rights on future drug sales, and licensing its proprietary technologies.

This strategy effectively de-risks biotech investing by creating a diversified portfolio of revenue streams supported by a lean corporate structure. The company’s goal is to offer shareholders a way to participate in the immense potential of the biotech industry without the binary risk typically associated with clinical trial outcomes.

Central to this model are Ligand’s two infrastructure-light technology platforms. The Captisol® platform is a chemically modified cyclodextrin used by partners to improve the solubility and stability of their drug compounds, making previously challenging formulations possible. The NITRICIL™ platform provides tunable drug-release capabilities, enabling partners to develop proprietary formulations for a wide array of indications. These technologies have been validated through numerous alliances with pharmaceutical giants, including Amgen, Merck, Pfizer, and Gilead Sciences, creating a steady flow of licensing fees and royalties.

Highlighting a Portfolio of Growth Drivers

During its presentations, management is expected to highlight the tangible assets fueling its revenue growth. The impressive 2025 royalty figures were driven by key partnered products, including Filspari for a rare kidney disease, Ohtuvayre for a severe lung condition, the vaccine adjuvant Capvaxive, and the cancer therapy Qarziba.

Filspari, marketed by partner Travere Therapeutics, will likely be a major focus. The drug generated U.S. net sales of $322 million in 2025, with fourth-quarter sales jumping 108% year-over-year. While the FDA recently extended its review of Filspari for a new indication, focal segmental glomerulosclerosis (FSGS), to April 2026, the underlying growth in its approved use remains exceptionally strong.

Beyond current revenue drivers, investors will be keen to hear updates on the broader pipeline of over 100 therapeutic assets. Key developments include partner Palvella Therapeutics' positive Phase 2 results for Qtorin rapamycin, with Phase 3 data expected in March 2026. Additionally, Sanofi's Tzield, for which Ligand holds royalty rights, is under FDA review to delay the progression of stage 3 type 1 diabetes, with a decision anticipated in the first half of 2026. These near-term catalysts demonstrate the depth and future potential of the portfolio Ligand has assembled.

Capitalizing on Opportunity

Armed with a formidable balance sheet that includes approximately $734 million in cash and over $1 billion in deployable capital, Ligand is in an enviable position to execute its growth strategy. The company has signaled its intent to be an active acquirer of new royalty assets and has recently implemented a new portfolio management process to unlock further value from its existing partnerships.

Wall Street has taken notice, with multiple analysts issuing "Buy" or "Outperform" ratings in recent months and a median price target of $237.0. While the stock has seen some volatility, the underlying sentiment reflects confidence in the company's financial strength and strategic direction. A recent filing for an at-the-market stock offering provides management with additional financial flexibility, enhancing its ability to act decisively on new opportunities.

As management takes the stage in Dana Point and New York, the investment community will be listening closely to how Ligand plans to deploy its capital and leverage its unique model to shape the next phase of its growth.